Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Priya Mathews

Cornea and External Diseases Specialist Venice, FL Medical Doctor

NPI 1124398102 CMS profile 1221049

1360 E Venice Ave, Venice, FL 34285

Open in the dashboard

General payments

$358,124

564 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$131,615 paid to institutions, not to them · program years 2023–2025

Through program year 2025, Priya Mathews of Venice, FL is reported in the CMS Open Payments database as having received $358,124 across 564 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $131,615 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Cornea and External Diseases Specialist profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $122,188 146
2024 General $93,976 121
2023 General $61,617 112
2022 General $44,765 88
2021 General $34,543 72
2020 General $583 19
2019 General $452 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Priya Mathews
  • Cornea and External Diseases Specialist median
  • Middle half of Cornea and External Diseases Specialist
  • National median

In program year 2025, general payments to Priya Mathews were reported at $122,188. Among 290 Cornea and External Diseases Specialist profiles paid that year, the median was $477 and the middle half received between $193 and $1,174.

Show as a table
Year Priya Mathews Cornea and External Diseases Specialist median Middle half National median
2019 $452 $276 $111–$734 $163
2020 $583 $146 $48–$330 $114
2021 $34,543 $254 $116–$566 $132
2022 $44,765 $251 $106–$729 $149
2023 $61,617 $344 $149–$759 $160
2024 $93,976 $366 $170–$927 $164
2025 $122,188 $477 $193–$1,174 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Sun Pharmaceutical Industries Inc. $73,820 112 payments
  2. W. L. Gore & Associates, Inc. $71,404 48 payments
  3. Johnson & Johnson Surgical Vision, Inc. $49,938 49 payments
  4. Oyster Point Pharma, Inc. $32,377 30 payments
  5. Alcon Vision LLC $31,442 57 payments
  6. AbbVie, Inc. $27,066 57 payments
  7. RxSight Inc $16,423 17 payments
  8. Dompe US, Inc. $15,221 27 payments
  9. Alcon Research LLC $8,901 3 payments
  10. Harrow Eye, LLC $7,195 19 payments
  11. Other $24,337 145 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $201,121 79 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $78,718 28 payments
  3. Honoraria $30,976 11 payments
  4. Travel and Lodging $20,633 73 payments
  5. Food and Beverage $17,658 366 payments
  6. Compensation for serving as faculty or as a speaker for a medical education program $9,000 6 payments
  7. Education $18 1 payment
Products named General payments · program years 2019–2025
  1. Cequa $73,820 112 payments
  2. Product in Development $71,404 48 payments
  3. Tecnis Simplicity $47,403 26 payments
  4. Tecnis IOL $45,799 17 payments
  5. TYRVAYA $24,814 24 payments
  6. TRYPTYR $22,080 11 payments
  7. RXSIGHT LIGHT DELIVERY DEVICE (LDD) $16,271 14 payments
  8. RXSIGHT CONTACT LENS $16,271 14 payments
  9. RXSIGHT INJECTOR CARTRIDGE $16,271 14 payments
  10. RXSIGHT INJECTOR HANDPIECE $16,271 14 payments
  11. Other $102,054 384 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 20 drugs

Part D claims

2,471

Median for Ophthalmology: 891

Drug cost

$270,371

Median for Ophthalmology: $68,233

Branded share of claims

42.8%

Median for Ophthalmology: 29.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Restasis Cyclosporine Brand 55 $56,572
Cequa Cyclosporine Brand 65 $49,792
Vevye Cyclosporine Brand 53 $38,227
Xiidra Lifitegrast Brand 30 $36,491
Prednisolone Acetate Generic 803 $24,315
Prolensa Bromfenac Sodium Brand 46 $16,173
Moxifloxacin Moxifloxacin Hcl Brand 590 $11,271
Cyclosporine Generic 19 $8,653
Lotemax Sm Loteprednol Etabonate Brand 30 $7,407
Ketorolac Tromethamine Generic 467 $6,330

The 10 drugs with the highest cost, of 20 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,260 Part D prescribers listed as Ophthalmology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$617,794

Medicare's payments for the services billed

Medicare patients

1,068

Average age 75

Services billed

4,193

684 women, 384 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 65%
Arthritis 49%
Ischemic heart disease 28%
Osteoporosis 23%
Depression 20%
Diabetes 19%
Chronic kidney disease 17%
Cancer 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Cequa
  • Sun Pharmaceutical Industries Inc. $10,781
$10,781 65 —
TYRVAYA
  • Oyster Point Pharma, Inc. $7,553
$7,553 — —
VEVYE
  • Harrow Eye, LLC $2,481
$2,481 53 —
DURYSTA
  • AbbVie, Inc. $1,425
$1,425 — —
LUMIGAN
  • AbbVie, Inc. $909
$909 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

564 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cornea and External Diseases Specialist in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record